Gerald Miletello

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels et al. · Journal for ImmunoTherapy of Cancer · 2019 · 147 citations · Full text

Medicine, Immunology, Oncology +14

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Ajjai Alva, Gregory A. Daniels, Michael K. Wong et al. · Cancer Immunology Immunotherapy · 2016 · 104 citations · Full text

Life Sciences, Immunology, Oncology +17

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

Mayer Fishman, Janice P. Dutcher, Joseph I. Clark et al. · Journal for ImmunoTherapy of Cancer · 2019 · 46 citations · Full text

Medicine, Immunology, Oncology +16

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Joseph I. Clark, Michael K. Wong, Howard L. Kaufman et al. · Clinical Genitourinary Cancer · 2016 · 34 citations · Full text

Medicine, Immunology, Oncology +15

Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2

Joseph I. Clark, Brendan D. Curti, Elizabeth J. Davis et al. · Journal of Investigative Medicine · 2021 · 22 citations · Full text

Medicine, Immunology, Oncology +16